Povofortay
Authorised
povorcitinib
MedicineHumanAuthorised
German is available via eTranslation, the European Commission's machine translation service.
Translate to German | Important information about machine translation
Povofortay is a medicine used in adults to treat hidradenitis suppurativa, also known as acne inversa. It is used to treat moderate-to-severe active disease when treatment with a medicine known as an anti-tumour necrosis factor (TNF) therapy has not worked well enough, is not tolerated or cannot be given.
Hidradenitis suppurativa is a long-term inflammatory skin condition that causes painful nodules (lumps) to develop under the skin, particularly in areas where skin rubs together. The nodules can become inflamed and form abscesses (collections of pus) resulting in scarring. Over time, they may connect to form tunnels under the skin.
Povofortay contains the active substance povorcitinib.
The medicine can only be obtained with a prescription. Treatment must be started and supervised by a doctor experienced in diagnosing and treating hidradenitis suppurativa.
Povofortay is available as tablets that are taken by mouth once a day. The dose depends on the severity of the condition, how well the treatment is working and the patient’s risk of blood clots, serious heart or blood circulation problems and cancer. For adults aged 65 years and older the lowest dose is recommended.
The doctor may consider stopping treatment if it has shown no benefit after 12 weeks.
For more information about using Povofortay, see the package leaflet or contact your doctor or pharmacist.
The active substance in Povofortay, povorcitinib, works by blocking the action of an enzyme (protein) known as Janus kinase 1. This enzyme is involved in the inflammation that causes the symptoms of hidradenitis suppurativa. By blocking its activity, povorcitinib helps reduce inflammation in the skin, thereby improving the signs and symptoms of the disease.
Two main studies involving a total of 1,227 adults with moderate-to-severe hidradenitis suppurativa compared Povofortay with placebo (a dummy treatment). The studies included 330 adults for whom anti-TNF treatment had not worked well enough, could not be tolerated or could not be given.
The main measure of effectiveness was the proportion of patients who had at least a 50% reduction in the combined number of abscesses and inflammatory nodules, without an increase in the number of abscesses or tunnels, after 12 weeks of treatment.
When the results for adults previously treated with anti-TNF therapy from both studies were looked at together, around 39% of those taking the lower dose of Povofortay and 36% of those taking the higher dose achieved this improvement. This compared with around 21% of adults who were given placebo.
Studies carried out with Povofortay are described in more detail in the medicine’s assessment report.
For the full list of side effects and restrictions with Povofortay, see the package leaflet.
The most common side effects with Povofortay (which may affect more than 1 in 10 people) include upper respiratory tract (nose and throat) infections and acne.
Povofortay must not be used in people with an active (ongoing) systemic (whole body) serious infection, including active tuberculosis. It must also not be used during pregnancy or breastfeeding.
Povofortay should only be used if no suitable treatment alternatives are available in patients aged 65 years or above, in patients with a history of cardiovascular disease (such as heart attack or stroke) or with risk factors for such a disease (such as current or previous long-term smokers), or in patients at increased risk of cancer (e.g. patients who have cancer or a history of cancer).
Povofortay reduced abscesses and inflammatory nodules without any increase in the number of abscesses or tunnels in adults with moderate-to-severe hidradenitis suppurativa for whom anti-TNF treatment had not worked well enough, could not be tolerated or could not be given. The Agency considered that these effects were meaningful in this group of patients whose disease was generally more difficult to treat and who had limited treatment options. The safety profile of povorcitinib was similar to that of other medicines that block Janus kinases and is considered manageable with the measures in place to minimise them.
The European Medicines Agency therefore decided that Povofortay’s benefits are greater than its risks and that it can be authorised for use in the EU.
The company that markets Povofortay will provide educational materials for healthcare professionals and patients. The materials explain the risks of serious infections, shingles, cancer, serious heart and blood-circulation problems and blood clots associated with Povofortay, and the measures used to manage these risks. The materials will also include a reminder that Povofortay should not be taken during pregnancy and that women who can become pregnant must use contraception (birth control) during treatment with Povofortay and for four weeks after stopping treatment.
These materials may be made available by national competent authorities on their websites. A list of national repositories is available on the EMA website.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Povofortay have also been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Povofortay are continuously monitored. Suspected side effects reported with Povofortay are carefully evaluated and any necessary action taken to protect patients.
Povofortay received a marketing authorisation valid throughout the EU on 12 November 2026.
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
Povofortay is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.